28345022|t|Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor
28345022|a|Allogeneic stem cell transplant -derived T cells have the potential to seek and eliminate sites of residual cancer that escaped primary therapy. Oncolytic myxoma virus (MYXV) exhibits potent anti-cancer efficacy against human cancers like multiple myeloma (MM) and can arm transplant -derived T cells to become more effective cancer killers in vitro and in an immunodeficient xenotransplant murine model. Here, we tested ex vivo MYXV virotherapy against residual murine MM in immunocompetent mice using an allogeneic mouse-mouse model. In contrast to all human MM cell lines previously tested, the murine MM cell line tested here was highly resistant to direct MYXV infection and oncolysis in vitro. Despite this in vitro resistance, we found that ex vivo MYXV -armed allogeneic bone marrow (BM) transplantation dramatically ablated pre-seeded residual MM in vivo. Unexpectedly, we show that both neutrophils and activated T cells from the donor function as virus-armed carrier cells, and MYXV -preloaded cells enhanced MM killing. Our results demonstrate a novel therapeutic paradigm for residual cancer, in which multiple classes of allotransplant leukocytes can be armed by MYXV ex vivo to enhance the graft-versus-tumor effects.
28345022	0	7	Ex Vivo	T169	C2348480
28345022	8	29	Oncolytic Virotherapy	T061	C1563738
28345022	35	47	Myxoma Virus	T005	C0027150
28345022	62	95	Allogeneic Bone Marrow Transplant	T061	C0398533
28345022	96	106	Leukocytes	T025	C0023516
28345022	118	136	Graft versus Tumor	T042	C0600555
28345022	137	168	Allogeneic stem cell transplant	T061	C4255274
28345022	178	185	T cells	T025	C0039194
28345022	236	251	residual cancer	T191	C0242594
28345022	265	280	primary therapy	T061	C1708063
28345022	282	291	Oncolytic	T080	C1518581
28345022	292	304	myxoma virus	T005	C0027150
28345022	306	310	MYXV	T005	C0027150
28345022	328	339	anti-cancer	T109,T121	C0003392
28345022	340	348	efficacy	T062	C1707887
28345022	357	362	human	T016	C0086418
28345022	363	370	cancers	T191	C0027651
28345022	376	392	multiple myeloma	T191	C0026764
28345022	394	396	MM	T191	C0026764
28345022	410	420	transplant	T061	C0040732
28345022	430	437	T cells	T025	C0039194
28345022	463	469	cancer	T191	C0027651
28345022	470	477	killers	T043	C1752435
28345022	478	486	in vitro	T080	C1533691
28345022	497	540	immunodeficient xenotransplant murine model	T015	C0599920
28345022	558	565	ex vivo	T169	C2348480
28345022	566	570	MYXV	T005	C0027150
28345022	571	582	virotherapy	T061	C1563738
28345022	600	606	murine	T015	C0025929
28345022	607	609	MM	T191	C0026764
28345022	613	628	immunocompetent	T201	C1512656
28345022	629	633	mice	T015	C0025929
28345022	643	671	allogeneic mouse-mouse model	T050	C2986594
28345022	692	711	human MM cell lines	T025	C0682523
28345022	735	754	murine MM cell line	T025	C1513528
28345022	778	787	resistant	T169	C0332325
28345022	798	802	MYXV	T005	C0027150
28345022	803	812	infection	T046	C3714514
28345022	817	826	oncolysis	T191	C0333516
28345022	827	835	in vitro	T080	C1533691
28345022	850	858	in vitro	T080	C1533691
28345022	859	869	resistance	T169	C4281815
28345022	885	892	ex vivo	T169	C2348480
28345022	893	897	MYXV	T005	C0027150
28345022	905	948	allogeneic bone marrow (BM) transplantation	T061	C0149615
28345022	990	992	MM	T191	C0026764
28345022	993	1000	in vivo	T082	C1515655
28345022	1034	1045	neutrophils	T025	C0027950
28345022	1060	1067	T cells	T025	C0039194
28345022	1077	1091	donor function	T043	C0007613
28345022	1095	1120	virus-armed carrier cells	T025	C0007634
28345022	1126	1130	MYXV	T005	C0027150
28345022	1142	1147	cells	T025	C0007634
28345022	1157	1159	MM	T191	C0026764
28345022	1160	1167	killing	T043	C1752435
28345022	1201	1212	therapeutic	T169	C0302350
28345022	1213	1221	paradigm	T062	C0681797
28345022	1226	1241	residual cancer	T191	C0242594
28345022	1272	1286	allotransplant	T061	C0040739
28345022	1287	1297	leukocytes	T025	C0023516
28345022	1314	1318	MYXV	T005	C0027150
28345022	1319	1326	ex vivo	T169	C2348480
28345022	1342	1368	graft-versus-tumor effects	T042	C0600555